Suspected oncologic adverse reactions associated with interleukin‐23 inhibitors in EudraVigilance: Comparative study and gender distribution

Abstract Psoriasis is a chronic inflammatory skin disease characterized by plaque formation. Interleukin (IL)‐23 is upregulated in psoriatic lesions and is thought to be a major regulator of the Th17 pathway in psoriasis pathogenesis. Three monoclonal antibodies targeting the IL‐23p19 subunit, gusel...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Fabrizio Calapai, Carmen Mannucci, Luigi Cardia, Mariaconcetta Currò, Gioacchino Calapai, Emanuela Esposito, Ilaria Ammendolia
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Wiley 2023-10-01
Sarja:	Pharmacology Research & Perspectives
Aiheet:	adverse reactions cancer guselkumab IL‐23 inhibitors pharmacovigilance psoriasis
Linkit:	https://doi.org/10.1002/prp2.1130
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!